Group 1 - The company has signed a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for the development of a new traditional Chinese medicine product [2][3] - The total technology transfer fee is set at 15 million yuan, which will be paid in installments as per the contract [6] - The contract includes provisions for intellectual property rights, ensuring that the technology and any resulting innovations will belong to the company, while the hospital retains certain academic rights [7][8] Group 2 - The technology being transferred involves the "Er Zhi Tiao Jing Optimization Formula," aimed at developing a new drug for treating conditions related to kidney deficiency [2][3] - The company is responsible for conducting all necessary research and regulatory submissions to achieve national drug registration for the new product [5] - The contract stipulates confidentiality obligations that extend for 20 years post-termination, ensuring that sensitive information remains protected [11][12] Group 3 - The contract outlines specific conditions under which either party can terminate the agreement, including failure to meet research milestones or submission deadlines [13][14] - Dispute resolution will be handled through negotiation, and if unresolved, will be taken to the competent court [17] - The contract is valid for 20 years and requires mutual consent for any amendments [20]

人民财讯8月15日电，步长制药（603858）8月15日晚间公告，控股子公司山东丹红拟与山东中医药大学 附属医院就二至调经优化方阶段性成果转让及其新药开发事宜签署《技术转让(开发)合同》，山东中医 药大学附属医院将其拥有的中药二至调经优化方的技术所有权以总价1500万元转让予山东丹红。 双方将依据合同约定，开展中药新药研究，成功开发出用于治疗肾虚、肾气阴虚所致的卵巢储备功能减 退等适应症的中药1.1类新药，最终获得国家药品注册证书，并实现该新药的工业化规模生产。 ...

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Group 1 - Guizhou Sanli plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University, with a total contract amount of RMB 150 million [1] - The technology contract involves the transfer of a patent for the use of Jinlv Banfenghe in the preparation of drugs for liver injury prevention and treatment, along with other related patents [1][2] - The patent transfer was successfully completed for RMB 50 million, with the transaction taking place on June 11, 2025 [1] Group 2 - The contract stipulates an overall transfer fee of RMB 50 million for the patent rights, with an initial payment of RMB 5 million due within 10 working days after signing [2] - The total development cost for the technical cooperation is RMB 100 million, with payments to be made in installments based on contract terms [2]